Quick Answer
Magnesium Threonate Cognition Randomized Trial has evidence relevant to safety, limits, and clinician-discussion contexts, but conclusions should stay close to the cited sources. One representative finding is: Results Compared to the placebo, Magtein ® was associated with greater improvements in overall cognitive performance as measured by the NIH Total Cognition Composite ( p = 0.043), with larger treatment effects on working and episodic memory.
Key Takeaways
- 01Results Compared to the placebo, Magtein ® was associated with greater improvements in overall cognitive performance as measured by the NIH Total Cognition Composite ( p = 0.043), with larger treatment effects on working and episodic memory. [Lopresti AL (2026)]
- 02Based on data from the sleep tracking ring, there were no group differences in sleep outcomes, although there was a greater reduction in HR ( p = 0.030) and an increase in HRV ( p = 0.036), a physiological marker of stress reduction and improved autonomic balance. [Lopresti AL (2026)]
- 03Conclusion The results from this study suggest Magtein ® supplementation for 6 weeks improves overall cognition, cognitive age, working memory, reaction time, HR, HRV, and some subjective, but not objective measures of sleep in healthy adults with self-reported dissatisfied sleep. [Lopresti AL (2026)]
- 04The purpose of this two-arm, 6-week, parallel-group, randomised, double-blind, placebo-controlled trial was to examine the effects of magnesium L-threonate (Magtein ® ) supplementation on cognitive performance, cognitive age, sleep quality, and selected physiological indicators in adults. [Lopresti AL (2026)]
The current Migaku evidence database contains 2 reusable source documents for Magnesium Threonate Cognition Randomized Trial. This answer focuses on safety, limits, and clinician-discussion contexts.
- Results Compared to the placebo, Magtein ® was associated with greater improvements in overall cognitive performance as measured by the NIH Total Cognition Composite ( p = 0.043), with larger treatment effects on working and episodic memory. [Lopresti AL (2026); evidence level 2]
- Based on data from the sleep tracking ring, there were no group differences in sleep outcomes, although there was a greater reduction in HR ( p = 0.030) and an increase in HRV ( p = 0.036), a physiological marker of stress reduction and improved autonomic balance. [Lopresti AL (2026); evidence level 2]
- Conclusion The results from this study suggest Magtein ® supplementation for 6 weeks improves overall cognition, cognitive age, working memory, reaction time, HR, HRV, and some subjective, but not objective measures of sleep in healthy adults with self-reported dissatisfied sleep. [Lopresti AL (2026); evidence level 2]
- The purpose of this two-arm, 6-week, parallel-group, randomised, double-blind, placebo-controlled trial was to examine the effects of magnesium L-threonate (Magtein ® ) supplementation on cognitive performance, cognitive age, sleep quality, and selected physiological indicators in adults. [Lopresti AL (2026); evidence level 2]
- Current research suggests that magnesium deficiency is associated with the development of depression, as magnesium influences glutamatergic and GABAergic neurotransmission, as well as the activity of the hypothalamic-pituitary-adrenal (HPA) axis, both of which play critical roles in stress responses and mood regulation. [Varga P (2025); evidence level 3]
Evidence levels are sorting aids, not final clinical grades. Level 1 usually indicates systematic-review style evidence, level 2 indicates randomized trials or public-health guidance, and lower levels need more cautious wording.
This page is educational. People with medical conditions, pregnancy, medication use, or unusual symptoms should ask a qualified clinician before changing supplements, medication, or treatment routines.
Sources